Skip to Main Content
Contribute Try STAT+ Today

Until the rising national anger over the cost of medicines, Novo Nordisk (NVO) retained a relatively low profile among drug makers. But as one of the three large purveyors of insulin, the Danish company has more recently occupied an uncomfortable spot in the limelight. Along with Sanofi (SNY) and Eli Lilly (LLY), the company has been accused of price gouging, collusion, and indifference to people with diabetes, some of whom are now driving from the U.S. to Canada to buy insulin. The events prompted Novo chief executive Lars Fruergaard Jorgensen to go on a “listening tour” in late June to sort out the problem. We met with him at the outset of his excursion and this is an edited version of our conversation.

Pharmalot: What do you hope to learn on this tour?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Phenomenal discussion of the very real human problems caused by the gross-to-net bubble. I wish more people read and understood this interview.

Comments are closed.